Published in J Biol Chem on January 02, 1998
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A (1998) 4.34
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol (1998) 3.23
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog (2012) 3.07
Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol (2000) 2.95
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol (2004) 1.79
Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 1.78
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol (1999) 1.75
NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci U S A (2005) 1.67
Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol (2000) 1.67
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil. Proc Natl Acad Sci U S A (1998) 1.58
Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J Virol (2000) 1.57
HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem (2012) 1.48
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol (2001) 1.38
Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol (2011) 1.30
Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol (2002) 1.30
Conformational intermediates and fusion activity of influenza virus hemagglutinin. J Virol (1999) 1.25
A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. J Virol (2006) 1.22
Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol (1999) 1.22
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect Dis (2002) 1.20
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol (2010) 1.17
Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association. J Virol (2001) 1.15
Expression and characterization of a soluble, active form of the jaagsiekte sheep retrovirus receptor, Hyal2. J Virol (2005) 1.13
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10
Functional implications of the human T-lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure. J Virol (2000) 1.08
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology (2006) 1.06
Physiological levels of virion-associated human immunodeficiency virus type 1 envelope induce coreceptor-dependent calcium flux. J Virol (2006) 1.04
Conformational changes in the capsid of a calicivirus upon interaction with its functional receptor. J Virol (2010) 0.99
Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of concept. Proc Natl Acad Sci U S A (2009) 0.98
Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J Virol (2000) 0.98
A soluble peripherin/Rds C-terminal polypeptide promotes membrane fusion and changes conformation upon membrane association. Exp Eye Res (2003) 0.96
Hairpin folding of HIV gp41 abrogates lipid mixing function at physiologic pH and inhibits lipid mixing by exposed gp41 constructs. Biochemistry (2009) 0.93
The peptide-binding and ATPase domains of recombinant hsc70 are required to interact with rotavirus and reduce its infectivity. J Virol (2006) 0.92
Sphingolipids, cholesterol, and HIV-1: a paradigm in viral fusion. Glycoconj J (2006) 0.91
Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol (2003) 0.91
C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. J Virol (2002) 0.91
Receptor-induced conformational changes in the SU subunit of the avian sarcoma/leukosis virus A envelope protein: implications for fusion activation. J Virol (2005) 0.90
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology (2007) 0.89
Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. Bioconjug Chem (2012) 0.88
Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag. Eur J Immunol (2010) 0.86
Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion. J Virol (2010) 0.86
Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J (2010) 0.84
Computer-Aided Approaches for Targeting HIVgp41. Biology (Basel) (2012) 0.82
A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion. Proc Natl Acad Sci U S A (1998) 0.82
Matrix and envelope coevolution revealed in a patient monitored since primary infection with human immunodeficiency virus type 1. J Virol (2009) 0.81
Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother (2004) 0.79
The SCHOOL of nature: IV. Learning from viruses. Self Nonself (2010) 0.77
HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses. J Immune Based Ther Vaccines (2009) 0.77
Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1. Virol J (2011) 0.76
Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. J Transl Med (2011) 0.76
Antiviral mode of action of bovine dialyzable leukocyte extract against human immunodeficiency virus type 1 infection. BMC Res Notes (2011) 0.76
Antiviral lectins: Selective inhibitors of viral entry. Antiviral Res (2017) 0.75
Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target? PLoS One (2016) 0.75
Use of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120. Anal Bioanal Chem (2009) 0.75
HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape. PLoS One (2013) 0.75
Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull (1993) 7.03
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. J Cell Biol (1999) 3.77
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol (1998) 3.23
Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane. J Virol (1990) 3.18
Membrane asymmetry in epithelia: is the tight junction a barrier to diffusion in the plasma membrane? Nature (1981) 3.01
Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker. Science (1977) 2.89
Restricted movement of lipid and aqueous dyes through pores formed by influenza hemagglutinin during cell fusion. J Cell Biol (1994) 2.87
Kinetics of pH-dependent fusion between 3T3 fibroblasts expressing influenza hemagglutinin and red blood cells. Measurement by dequenching of fluorescence. J Biol Chem (1989) 2.82
Initial stages of influenza hemagglutinin-induced cell fusion monitored simultaneously by two fluorescent events: cytoplasmic continuity and lipid mixing. J Cell Biol (1989) 2.40
Lateral diffusion of surface immunoglobulin, Thy-1 antigen, and a lipid probe in lymphocyte plasma membranes. Proc Natl Acad Sci U S A (1979) 2.29
Design of liposomes for enhanced local release of drugs by hyperthermia. Science (1978) 2.17
Kinetics of the opening and closing of individual excitability-inducing material channels in a lipid bilayer. J Gen Physiol (1974) 2.15
HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry (2001) 2.07
The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Virology (1993) 2.05
Interferon-beta is required for interferon-alpha production in mouse fibroblasts. Curr Biol (1998) 1.95
What studies of fusion peptides tell us about viral envelope glycoprotein-mediated membrane fusion (review). Mol Membr Biol (1998) 1.94
[Indications for implantable cardioverter-defibrillator]. Dtsch Med Wochenschr (2002) 1.94
Conformational changes and fusion activity of influenza virus hemagglutinin of the H2 and H3 subtypes: effects of acid pretreatment. J Virol (1990) 1.91
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Charge clusters and the orientation of membrane proteins. J Membr Biol (1982) 1.87
Delay time for influenza virus hemagglutinin-induced membrane fusion depends on hemagglutinin surface density. J Virol (1991) 1.87
Voltage-dependent trans-bilayer orientation of melittin. J Biol Chem (1982) 1.86
The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem (2000) 1.79
pH-dependent lysis of liposomes by adenovirus. Biochemistry (1986) 1.74
Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol (2000) 1.67
[A theory of electric excitation of biological membranes]. C R Acad Sci Hebd Seances Acad Sci D (1970) 1.63
Gating kinetics of pH-activated membrane fusion of vesicular stomatitis virus with cells: stopped-flow measurements by dequenching of octadecylrhodamine fluorescence. Biochemistry (1990) 1.63
AIDS vaccine development. Science (1998) 1.62
Observation of single influenza virus-cell fusion and measurement by fluorescence video microscopy. Proc Natl Acad Sci U S A (1990) 1.58
The use of fluorescence dequenching measurements to follow viral membrane fusion events. Methods Biochem Anal (1988) 1.56
Micelle-vesicle transition of egg phosphatidylcholine and octyl glucoside. Biochemistry (1988) 1.54
Diffusion and patching of macromolecules on planar lipid bilayer membranes. Biochemistry (1977) 1.51
Liposomes as targets for granule cytolysin from cytotoxic large granular lymphocyte tumors. Proc Natl Acad Sci U S A (1984) 1.49
Activation of vesicular stomatitis virus fusion with cells by pretreatment at low pH. J Biol Chem (1988) 1.45
Absorption and hemodynamic effects of airway administration of adrenaline in patients with severe cardiac disease. Ann Intern Med (2000) 1.44
Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1992) 1.44
pH-dependent fusion induced by vesicular stomatitis virus glycoprotein reconstituted into phospholipid vesicles. J Biol Chem (1984) 1.44
Bimodal RR interval distribution in chronic atrial fibrillation: impact of dual atrioventricular nodal physiology on long-term rate control after catheter ablation of the posterior atrionodal input. J Cardiovasc Electrophysiol (2000) 1.42
Role of the fusion peptide sequence in initial stages of influenza hemagglutinin-induced cell fusion. J Biol Chem (1993) 1.40
Interaction of tubulin with phospholipid vesicles. I. Association with vesicles at the phase transition. J Biol Chem (1981) 1.40
[Therapy of atrial fibrillation]. Internist (Berl) (2003) 1.40
Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem (2001) 1.39
Kinetics of HIV-1 interactions with sCD4 and CD4+ cells: implications for inhibition of virus infection and initial steps of virus entry into cells. Virology (1992) 1.34
Initial stages of HIV-1 envelope glycoprotein-mediated cell fusion monitored by a new assay based on redistribution of fluorescent dyes. AIDS Res Hum Retroviruses (1991) 1.32
What do culturally sensitive mental health services mean? The case of Hispanics. Am Psychol (1987) 1.28
Conformational intermediates and fusion activity of influenza virus hemagglutinin. J Virol (1999) 1.25
The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1998) 1.23
Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study. J Biol Chem (1997) 1.21
Single cell fusion events induced by influenza hemagglutinin: studies with rapid-flow, quantitative fluorescence microscopy. Exp Cell Res (1991) 1.20
Phase transition release, a new approach to the interaction of proteins with lipid vesicles. Application to lipoproteins. Biochim Biophys Acta (1981) 1.19
A long-lived state for influenza virus-erythrocyte complexes committed to fusion at neutral pH. FEBS Lett (1992) 1.19
Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction. J Virol (1993) 1.16
Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry (2006) 1.14
Voltage-dependent translocation of the asialoglycoprotein receptor across lipid membranes. Nature (1980) 1.14
Conformational changes and fusion activity of vesicular stomatitis virus glycoprotein: [125I]iodonaphthyl azide photolabeling studies in biological membranes. Biochemistry (1997) 1.14
Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1994) 1.13
Kinetics of the low pH-induced conformational changes and fusogenic activity of influenza hemagglutinin. Biophys J (1994) 1.13
Reconstitution of the hepatic asialoglycoprotein receptor with phospholipid vesicles. Proc Natl Acad Sci U S A (1980) 1.13
Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc Natl Acad Sci U S A (1980) 1.09
On the use of self-quenching fluorophores in the study of membrane fusion kinetics. The effect of slow probe redistribution. Biophys Chem (1989) 1.09
Intermediates in influenza virus PR/8 haemagglutinin-induced membrane fusion. J Gen Virol (1994) 1.08
Analyzing the fusion process of influenza hemagglutinin by mutagenesis and molecular modeling. Biophys J (1992) 1.08
Liposome--lymphocyte interaction: saturable sites for transfer and intracellular release of liposome contents. Proc Natl Acad Sci U S A (1977) 1.07
Complications of pacemaker-defibrillator devices: diagnosis and management. Am Heart J (1994) 1.06
Hemagglutinin-neuraminidase enhances F protein-mediated membrane fusion of reconstituted Sendai virus envelopes with cells. J Virol (1993) 1.05
Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardiothorac Vasc Anesth (1998) 1.03
Noninvasive diagnosis in patients with undocumented tachycardias: value of the adenosine test to predict AV nodal reentrant tachycardia. J Cardiovasc Electrophysiol (1999) 1.03
Gangliosides do not move from apical to basolateral plasma membrane in cultured epithelial cells. Biochim Biophys Acta (1985) 1.01
Escherichia coli outer membrane protein K is a porin. J Bacteriol (1983) 1.01
Purification and characterization of the inducible lactose-specific membrane-bound component of the staphylococcal phosphenolpyruvate-dependent phosphotransferase system. Eur J Biochem (1971) 1.01
Detection of membrane cholesterol by filipin in isolated rat liver coated vesicles is dependent upon removal of the clathrin coat. J Cell Biol (1984) 1.00
Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells. Biochem Biophys Res Commun (1998) 1.00
Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell Mol Life Sci (2008) 1.00
Interaction of liver clathrin coat protein with lipid model membranes. J Biol Chem (1982) 1.00
Composition of octyl glucoside-phosphatidylcholine mixed micelles. Biochemistry (1988) 0.99
Interaction of influenza hemagglutinin amino-terminal peptide with phospholipid vesicles: a fluorescence study. Biochemistry (1991) 0.99
Clathrin-induced pH-dependent fusion of phosphatidylcholine vesicles. J Biol Chem (1983) 0.99
Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J Biol Chem (2001) 0.99
The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells. J Virol (1994) 0.98
Varying effects of temperature, Ca(2+) and cytochalasin on fusion activity mediated by human immunodeficiency virus type 1 and type 2 glycoproteins. FEBS Lett (2000) 0.98
Seasonal variation in intraocular pressure. Am J Ophthalmol (1970) 0.97
Detection of influenza hemagglutinin interaction with biological membranes by photosensitized activation of [125I]iodonaphthylazide. J Biol Chem (1994) 0.97
Kinetics of cell fusion mediated by viral spike glycoproteins. Methods Enzymol (1993) 0.97
Interaction of tubulin with phospholipid vesicles. II. Physical changes of the protein. J Biol Chem (1981) 0.96
Correspondence of genotypes of sporadic Yersinia enterocolitica bioserotype 4/O:3 strains from human and porcine sources. Epidemiol Infect (2001) 0.96
Antibody-mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells. Biochim Biophys Acta (1978) 0.96
Transmission of Yersinia enterocolitica 4/O:3 to pets via contaminated pork. Lett Appl Microbiol (2001) 0.95
Cell fusion mediated by interaction of a hybrid CD4.CD8 molecule with the human immunodeficiency virus type 1 envelope glycoprotein does occur after a long lag time. J Virol (1993) 0.95
Membrane-induced conformational change during the activation of HIV-1 gp41. J Mol Biol (2000) 0.95
Interaction of lymphocytes with lipid bilayer membranes: a model for lymphocyte-mediated lysis of target cells. Proc Natl Acad Sci U S A (1975) 0.94
Sizing and separation of liposomes, biological vesicles, and viruses by high-performance liquid chromatography. Anal Biochem (1986) 0.93
The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci (2006) 0.93
The role of cytoplasmic granules in cytotoxicity by large granular lymphocytes and cytotoxic T lymphocytes. Adv Exp Med Biol (1985) 0.93
Atrial reentrant tachycardia after surgery for congenital heart disease: endocardial mapping and radiofrequency catheter ablation using a novel, noncontact mapping system. Circulation (2001) 0.93
Heat-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing HIV-1 envelope glycoproteins. Virology (1996) 0.93
Fusion of Sendai virions with phosphatidylcholine-cholesterol liposomes reflects the viral activity required for fusion with biological membranes. FEBS Lett (1985) 0.92